**July 2026** Every day, researchers around the world publish new findings about ovarian cancer. Some are early lab experiments, some are large clinical trials, and some are reviews that pull together everything we currently know about a topic. This digest looks at everything published in **July 2026** that is relevant to ovarian, fallopian tube, or peritoneal cancer, so you don't have to comb through dozens of medical journals yourself. This month's research touched on six broad areas: sharpening how we use PARP inhibitors (a mainstay maintenance therapy), new strategies for the toughest cases: cancer that has stopped responding to platinum chemotherapy, progress and setbacks in immunotherapy and targeted drugs, promising but early tools for catching ovarian cancer sooner, updates on surgical technique and safety, and questions many patients ask about diet, environment, and the body during treatment. As always, most of what's below is still in the research pipeline rather than in the clinic today. We've labeled the stage of every study so you can tell the difference between "available now," "in clinical trials," and "early lab research that's years away, if it pans out at all." *The papers highlighted here represent a selection of those published during the month. The papers were selected and summarized by AI. Accuracy of the summaries was confirmed by a scientist.* This digest incorporates only open-access research articles that are free to be read by the entire community and that are explicitly licensed to be shared and reused. --- **Sharpening How We Use PARP Inhibitors** PARP inhibitors (drugs like olaparib, niraparib, and rucaparib that block an enzyme cancer cells rely on to repair their DNA) are already a standard part of ovarian cancer maintenance treatment, especially for tumors with a BRCA mutation or other DNA-repair problems. This month's research focused on getting more precise about who benefits, and how to make the drugs work harder. - **A large profiling program found that DNA-repair-deficiency testing catches more eligible patients than genetic testing alone.** Homologous recombination deficiency (HRD, a broad problem with a tumor's ability to repair its own DNA) predicts who responds to PARP inhibitors, but standard genetic testing for BRCA mutations misses many people who still have it. In this study of over 500 tumor samples, HRD showed up in 52% of high-grade ovarian cancers, and lab tests like RAD51 staining and a "genomic instability score" identified it even in tumors with no known BRCA mutation. The study also tracked how BRCA mutations can "revert" (essentially un-break themselves) after PARP inhibitor treatment, which helps explain why some tumors stop responding. This is a retrospective analysis of banked clinical samples, not a treatment trial, but it strengthens the case for using more than one type of HRD test rather than relying on BRCA testing alone. (DOI: [10.1038/s41698-026-01583-y](https://doi.org/10.1038/s41698-026-01583-y)) - **Combining a PARP inhibitor with a second targeted drug slowed tumor growth in lab models of resistant ovarian cancer.** Researchers paired niraparib (a PARP inhibitor) with lapatinib (a drug that blocks the EGFR/HER2 growth-signaling receptor) and found the combination worked better together than either drug alone in ovarian cancer cells and in mice, including suppressing the cells' ability to spread. This is early-stage laboratory and animal research, not yet tested in people, but it points to a possible strategy for overcoming PARP inhibitor resistance down the road. (DOI: [10.4143/crt.2025.553](https://doi.org/10.4143/crt.2025.553)) - **A review lays out the case for using PARP inhibitors before surgery, not just after.** Right now, PARP inhibitors are mainly used as "maintenance" therapy after chemotherapy. This review pulls together ongoing clinical trials testing whether giving a PARP inhibitor beforehand could shrink tumors enough to make surgery more complete, particularly for BRCA-mutated or HRD-positive disease. The authors are candid that this remains unproven and raises real concerns: delayed surgery, wound-healing problems, and blood-count side effects that could complicate an operation. This is a narrative review of the current evidence and trial landscape, not new trial data. (DOI: [10.3390/cancers18132157](https://doi.org/10.3390/cancers18132157)) - **PARP inhibitors help older patients too, but with a higher rate of side effects to watch for.** A meta-analysis pooling 13 randomized trials found that olaparib, rucaparib, and niraparib all significantly slowed disease progression in patients 65 and older, similar benefit to younger patients but with higher rates of blood-count and gastrointestinal side effects. Older adults have historically been underrepresented in ovarian cancer trials, so this analysis is a useful data point for oncologists making treatment decisions with older patients. This is a meta-analysis of existing randomized trial data, the strongest form of evidence short of a dedicated new trial. (DOI: [10.3389/fonc.2026.1875768](https://doi.org/10.3389/fonc.2026.1875768)) - **New lab evidence helps resolve some "uncertain" BRCA1 genetic test results.** When a genetic test finds a change in the BRCA1 gene that doesn't match a well-known "pathogenic" or "benign" pattern, it's reported as a Variant of Uncertain Significance (VUS), which can leave patients and families without a clear answer about their risk. This study combined computer modeling with lab experiments to test how a set of BRCA1 variants in a specific gene region actually behave and was able to confidently reclassify four of them (three as likely benign, one as likely harmful). This kind of work, multiplied across the many known VUS results, is slowly closing the "uncertain" gap that affects real families making decisions about prophylactic surgery or enhanced screening. This is a laboratory and computational study. (DOI: [10.3390/curroncol33070399](https://doi.org/10.3390/curroncol33070399)) *Check the citations section for a comprehensive list of publications associated with this topic.* --- **New Strategies for Platinum-Resistant Disease** Platinum-based chemotherapy (carboplatin or cisplatin) is the backbone of ovarian cancer treatment, but many tumors eventually stop responding - a turning point that historically has meant far fewer good options. This was a significant month for platinum-resistant disease research. - **A large Phase 3 trial found that adding a hormone-receptor-blocking drug to chemotherapy improved survival in platinum-resistant ovarian cancer.** The ROSELLA trial tested relacorilant, a drug that blocks the glucocorticoid receptor (a stress-hormone signaling pathway that tumors can hijack to resist chemotherapy), added to standard nab-paclitaxel chemotherapy. This review of the trial reports that the combination significantly improved both progression-free survival and overall survival compared to chemotherapy alone in recurrent platinum-resistant disease, a setting where new options are badly needed. This is a Phase 3 randomized clinical trial, the highest level of evidence in cancer research, and represents one of the more clinically significant results in this month's search. (DOI: [10.3389/or.2026.1861081](https://doi.org/10.3389/or.2026.1861081)) - **A molecular "fingerprint" may help explain why some high-grade serous tumors resist platinum chemotherapy.** By analyzing the proteins and metabolic byproducts of 97 tumor samples, researchers identified a subtype of high-grade serous ovarian cancer with a distinct pattern of fat metabolism and inflammation, and a markedly higher platinum resistance rate (64.5%) and worse survival. The subtype was linked to a specific inflammatory pathway (involving an enzyme called COX-2) that is already targeted by existing anti-inflammatory drugs in other contexts, suggesting a possible future angle for combination treatment, though this study did not test any drug. This is a molecular profiling study of banked tumor samples. (DOI: [10.1002/advs.76482](https://doi.org/10.1002/advs.76482)) - **An AI model showed strong results predicting which patients will develop platinum-resistant recurrence, but with important caveats.** Researchers built a multimodal artificial intelligence model combining clinical records, imaging (CT/MRI), and medical literature to predict which patients would relapse within 6 months of finishing platinum chemotherapy. The model performed very well in this single-center dataset, but the authors themselves are explicit that it is "preliminary," has not been tested at any other hospital, and "is not ready for clinical use." This is an exploratory, single-center proof-of-concept study; it should be read as a promising research direction, not a tool you could ask your doctor about today. (DOI: [10.3389/fmed.2026.1842344](https://doi.org/10.3389/fmed.2026.1842344)) *Check the citations section for a comprehensive list of publications associated with this topic.* --- **Immunotherapy and Targeted Therapy: Progress on a Historically Hard Problem** Ovarian cancer has been notoriously resistant to immunotherapy compared to some other cancers, but researchers keep testing new angles, from re-engineered immune cells to combination strategies. - **An early-phase trial of a bispecific "T-cell engager" drug showed activity in a majority-ovarian-cancer patient group.** The drug, IMC-C103C, works by physically bringing a patient's own T cells into contact with tumor cells that display a particular protein (MAGE-A4). In this Phase 1/2 trial, 64% of the dose-escalation group had ovarian carcinoma, plus a dedicated ovarian cancer expansion group. At higher doses, some patients with MAGE-A4-expressing tumors had meaningful tumor shrinkage and lived longer, though the protein's expression was often "low," which limited how well the drug could be evaluated. Side effects were manageable and mostly related to the immune system revving up (cytokine release syndrome). This is an early-phase (Phase 1/2) clinical trial. (DOI: [10.1136/jitc-2025-014638](https://doi.org/10.1136/jitc-2025-014638)) - **Researchers redesigned a CAR T-cell therapy to solve a problem that has held it back in ovarian cancer.** CAR T-cell therapy (genetically engineering a patient's own immune cells to attack a specific target) has struggled against a protein called mesothelin because tumor cells shed it into the bloodstream, where it acts as a decoy that distracts the engineered T cells before they reach the tumor. This study built CAR T-cells that specifically recognize the small "stump" of mesothelin left behind after shedding, which the decoy version doesn't have. The redesigned cells worked as well as before, but weren't fooled by the decoy. This is laboratory and mouse-model research, an early but clever step toward making mesothelin-targeted CAR T therapy more effective. (DOI: [10.3389/fimmu.2026.1805950](https://doi.org/10.3389/fimmu.2026.1805950)) - **A combination approach restored a cancer vaccine's effectiveness in BRCA1-deficient tumors.** In mouse models, a dendritic cell-based cancer vaccine worked well against BRCA2-deficient ovarian tumors but not BRCA1-deficient ones, because BRCA1-deficient tumors created an environment where T cells became "exhausted" (worn out and less able to fight) before the vaccine could help. Adding drugs that block blood vessel growth and PARP, plus a checkpoint inhibitor, partially restored the vaccine's effectiveness. This is preclinical mouse research, but it's a useful reminder that BRCA1- and BRCA2-mutated ovarian cancers may need different immunotherapy strategies, not one-size-fits-all. (DOI: [10.1016/j.isci.2026.116587](https://doi.org/10.1016/j.isci.2026.116587)) - **Two review articles this month took stock of where engineered-immune-cell and antibody-drug conjugate research stands for ovarian and other gynecologic cancers.** One review focused specifically on CAR-T and TCR-T cell approaches (engineered T cells) in high-grade serous ovarian cancer, noting encouraging early lab results but acknowledging the field is still working out how to get these cells to work as well in solid tumors as they do in blood cancers. (DOI: [10.1186/s43046-026-00389-0](https://doi.org/10.1186/s43046-026-00389-0)) A second, broader review covered checkpoint inhibitors and antibody-drug conjugates (ADCs, antibodies chemically attached to a cell-killing drug, designed to deliver the drug directly to cancer cells) across endometrial, cervical, and ovarian cancer, highlighting that checkpoint inhibitors alone have shown limited benefit in unselected ovarian cancer patients, while folate-receptor-alpha- and HER2-targeted ADCs are emerging as more promising, biomarker-guided options. (DOI: [10.3390/cancers18142342](https://doi.org/10.3390/cancers18142342)) - **A lab study offers a possible explanation for why an already-approved ADC might work better in combination.** Trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate already FDA-approved for HER2-expressing cancers, was tested against ovarian tumor samples from 130 patients. Tumors with high HER2 levels also had more of a particular immune signal (PD-L1) and immune cell type, and combining T-DXd with the anti-blood-vessel drug bevacizumab produced a stronger effect in the lab than either alone. This is a retrospective, correlative lab study using patient samples, not a treatment trial, but it may help inform future combination-therapy trials. (DOI: [10.3389/fonc.2026.1867768](https://doi.org/10.3389/fonc.2026.1867768)) *Check the citations section for a comprehensive list of publications associated with this topic.* --- **Toward Earlier Detection** Ovarian cancer is so often diagnosed late partly because there's no reliable early-detection test. This remains one of the field's biggest unmet needs, and this month brought several early-stage attempts at closing that gap. - **A basic-science discovery in the fallopian tube, where many ovarian cancers actually start, may point toward future prevention strategies.** High-grade serous ovarian cancer is now understood to often originate in the fallopian tube, not the ovary itself. This study found that certain long-lived immune cells (called tissue-resident memory T cells) in normal fallopian tube tissue share significant overlap with immune cells found inside tumors, and that these fallopian-tube cells can recognize and respond to a patient's own tumor cells in lab experiments, suggesting the fallopian tube may host a natural, if incomplete, immune surveillance system against early cancer development. This is basic laboratory science using patient tissue samples, published in Nature Communications; it's a mechanistic discovery, not a test or treatment, but it deepens the biological rationale for prevention research focused on the fallopian tube. (DOI: [10.1038/s41467-026-74599-4](https://doi.org/10.1038/s41467-026-74599-4)) - **A blood test measuring three microRNAs showed moderate accuracy for spotting ovarian cancer.** MicroRNAs are small molecules that circulate in the blood and can be altered by cancer. Two of the three tested here were significantly lower in ovarian cancer patients than in healthy volunteers, with moderate accuracy (about 70–73% on a common accuracy scale where 100% is perfect and 50% is a coin flip). This is a case-control study comparing 77 patients to 74 healthy volunteers, which is a useful early step, but moderate accuracy alone isn't enough for a real-world screening test, and the authors call for larger, multi-center validation. (DOI: [10.1038/s41598-026-60116-6](https://doi.org/10.1038/s41598-026-60116-6)) - **A more sophisticated blood test using cell-free RNA showed much higher accuracy in early testing.** This test analyzes fragments of RNA that leak into the bloodstream from cells throughout the body (cell-free RNA, or cfRNA) using a deep-learning model. In this study of 304 people, it distinguished ovarian cancer patients from healthy controls with very high accuracy, and separately, predicted which patients would become chemotherapy-resistant. This is a promising early-stage diagnostic study (with training and test sets, and a registered trial number), but this kind of very high performance in a single study needs to be replicated in bigger, more diverse groups before it means anything for real-world screening. Deep-learning models can sometimes look excellent in the exact dataset they were built on and perform less well elsewhere. (DOI: [10.1002/advs.76274](https://doi.org/10.1002/advs.76274)) - **A low-cost sensor technology combining DNA-wrapped carbon nanotubes with machine learning showed promise for detecting several cancers, including ovarian, from a blood sample.** The technology reads a "fluorescent fingerprint" from a blood sample and uses machine learning to classify whether cancer is present, estimated at roughly $4 per test. In a study spanning 253 blood samples across liver, lung, and ovarian cancers, it correctly identified cancer 89% of the time on average, and correctly ruled out cancer 96% of the time. Ovarian cancer was one of three cancer types studied, not the sole focus, and, like the cfRNA study above, this needs replication in larger, independent samples before it could become a real screening tool. This is early-stage technology-development research. (DOI: [10.1126/sciadv.aef9530](https://doi.org/10.1126/sciadv.aef9530)) - **A review article rounds up where nanotechnology-based diagnosis and treatment stand for ovarian cancer.** The review covers gold nanoparticles, quantum dots, and other nanoscale tools being explored for detecting cancer biomarkers earlier and more precisely, plus nanoparticle-based drug delivery (an approach already used clinically in some chemotherapy formulations, like Doxil). It's a helpful primer on the landscape, but as the authors note, most of what's covered remains in preclinical or early clinical testing. (DOI: [10.3390/cells15141248](https://doi.org/10.3390/cells15141248)) *Check the citations section for a comprehensive list of publications associated with this topic.* --- **Surgery: Advances and Safety** Surgery to remove as much visible tumor as possible (cytoreductive or "debulking" surgery) remains central to ovarian cancer treatment, and this month's research touched on technique, patient selection, and safety. - **A "hybrid" surgical technique combining robotic and traditional open surgery achieved no visible remaining tumor in 95% of a small patient group.** Surgeons used robotic-assisted surgery for the pelvic portion of the operation and a smaller traditional open incision for the upper abdomen, in 20 patients with advanced (stage III-IV) ovarian cancer. The approach achieved complete removal of visible tumor in 19 of 20 patients, with an average hospital stay of 8 days. This is a feasibility study without a comparison group, so it can't yet tell us whether this hybrid approach is actually better than standard techniques, but it demonstrates the approach is workable and worth testing further. (DOI: [10.5468/ogs.26044](https://doi.org/10.5468/ogs.26044)) - **A proposed framework aims to identify which patients actually benefit from extensive lymph node removal during surgery.** Major trials (LION and CARACO) previously found that routinely removing pelvic and abdominal lymph nodes that don't look abnormal doesn't improve survival for most patients, while adding surgical risk. This paper proposes using molecular markers of chemotherapy resistance to identify the minority of patients for whom more extensive lymph node removal might still be worthwhile — the idea being that resistant cancer cells can sometimes "hide" in lymph nodes. This is a conceptual/hypothesis-generating review, not new trial data; it’s a roadmap for future research rather than a practice change today. (DOI: [10.3389/fmed.2026.1883825](https://doi.org/10.3389/fmed.2026.1883825)) - **A large database study quantified the risk of sepsis (a serious, body-wide infection response) after ovarian cancer surgery.** Looking at nearly 39,000 patients in a U.S. national hospital database, researchers found a 3.3% rate of postoperative sepsis, with higher risk linked to older age, certain pre-existing health conditions (like heart failure and clotting disorders), and cancer that had spread. Sepsis was associated with longer hospital stays, higher costs, and higher in-hospital death rates. This is a large retrospective database study; it doesn't change surgical practice on its own, but it helps identify which patients may need closer monitoring after surgery. (DOI: [10.1371/journal.pone.0353675](https://doi.org/10.1371/journal.pone.0353675)) *Check the citations section for a comprehensive list of publications associated with this topic.* --- **Diet, Environment, and the Body During Treatment** Patients and caregivers often ask about the everyday factors within their control: diet, chemical exposures, fertility treatments, and what chemotherapy does to the body beyond the tumor itself. This month's literature had a few relevant, if mostly preliminary, answers. - **A large study found that fertility treatments are not meaningfully linked to a higher risk of ovarian cancer once underlying fertility conditions are accounted for.** Using health records for over 1.7 million Australian women, including nearly 400,000 who had undergone fertility treatment, researchers found a modest statistical association between fertility treatment and several hormone-related cancers, including ovarian cancer, but their analysis suggests this may be explained by the underlying conditions (like endometriosis or polycystic ovarian syndrome) that led patients to need fertility treatment in the first place, rather than the treatment itself. The actual number of extra cancer cases was small (fewer than 20 per 100,000 women per year for any single cancer type). This is a large, well-designed cohort study using a "target trial emulation" statistical design, though like all observational research it cannot fully rule out unmeasured factors. (DOI: [10.1001/jamanetworkopen.2026.22832](https://doi.org/10.1001/jamanetworkopen.2026.22832)) - **A diet-quality review found the evidence linking healthy eating patterns to ovarian cancer risk specifically is still limited.** The review looked at how well-studied diet patterns (the DASH diet, Mediterranean diet, and plant-based diets) relate to cancer risk in women. It found fairly consistent evidence that these diets are associated with lower colorectal and breast cancer risk, but the authors are direct that evidence for ovarian cancer specifically "remains limited and inconclusive." This is a narrative review of existing studies, not new data, and serves as a useful, honest reminder that not every cancer-prevention claim about diet has equally strong evidence behind it yet. (DOI: [10.3390/nu18132155](https://doi.org/10.3390/nu18132155)) - **A lab study found that "forever chemicals" (PFAS) can alter how ovarian cells respond to chemotherapy.** PFAS are a group of manufactured chemicals found in some water supplies, food packaging, and consumer products, known for persisting in the body and environment. In a lab study using mouse ovarian cells, brief exposure to PFAS reduced the cells' sensitivity to two chemotherapy drugs (cabazitaxel and docetaxel), while longer exposure had the opposite effect. This is early laboratory research in mouse cells, not human ovarian cancer cells or patients, so it raises a question worth further study rather than establishing a clear real-world risk. (DOI: [10.3390/ijms27146301](https://doi.org/10.3390/ijms27146301)) - **A study tracked how chemotherapy reshapes gut bacteria over the course of ovarian cancer treatment.** Researchers followed patients' gut microbiome (the community of bacteria living in the digestive tract) over time during chemotherapy and found consistent shifts in bacterial composition. Gut bacteria changes have been linked in other cancers to side effects like nausea and diarrhea, and to how well the immune system responds to treatment, though this study's focus was describing the changes rather than testing an intervention. This is a prospective longitudinal (over-time) observational study. (DOI: [10.1186/s12967-026-08731-9](https://doi.org/10.1186/s12967-026-08731-9)) *Check the citations section for a comprehensive list of publications associated with this topic.* --- --- **Epidemiology, Access & Health Disparities Research** Population-level studies on ovarian cancer incidence, survival disparities, and access to care that are confirmed on-topic for this month but didn't fit neatly into the patient-facing themes above. *Check the citations section for a comprehensive list of publications associated with this topic.* --- **General & Basic-Science Research** Laboratory and molecular studies, such as investigating gene/pathway mechanisms, rare-tumor pathology, single-cell and omics profiling, that are confirmed on-topic for ovarian, fallopian tube, or peritoneal cancer, but are too technical or narrow for the patient-facing themes above. *Check the citations section for a comprehensive list of publications associated with this topic.* --- **What Does This Mean for Me?** If you or someone you love is currently on a **PARP inhibitor**, this month's research doesn't change your treatment, but it reinforces that testing for DNA-repair problems (HRD) is more nuanced than a single BRCA test, and that the drugs' benefits appear to hold up even for older patients - both good conversation topics for your next oncology visit. If you or a family member has ever received a BRCA genetic test result that came back as "uncertain," know that scientists are actively working through that backlog of ambiguous results one variant at a time; it's worth checking back with a genetic counselor periodically, since a variant reported as uncertain today may be reclassified later. If platinum-resistant disease is part of your story, the **ROSELLA trial** result is the most immediately relevant news this month; it's a Phase 3 trial, meaning it's the kind of evidence that can (and often does) lead to a new treatment option, so it's a reasonable question to raise with your oncologist about whether relacorilant might become available or already fits into your care. Nothing this month suggests a new blood test for **early detection** is close to being available. The microRNA, cfRNA, and nanotube-sensor studies are all encouraging directions, but each needs to be tested in far larger and more diverse groups of people before any of them could become a real screening tool. If you're navigating decisions about extensive surgery or lymph node removal, know that the field is actively working to move away from "remove everything, just in case" toward more selective, evidence-based approaches - a shift that's ultimately about sparing patients unnecessary surgical risk. Finally, if you've wondered whether **fertility treatments** raised your ovarian cancer risk, this month's largest study is reassuring: the modest signal researchers see appears to be explained by the reasons someone needed fertility treatment in the first place, not the treatment itself, and the real-world number of extra cancer cases either way is small. And if you're looking for dietary changes that clearly reduce ovarian cancer risk specifically, the honest answer from this month's review is that the evidence isn't there yet. General healthy-eating patterns are reasonable for overall health, but nobody can point you to strong, ovarian-cancer-specific dietary evidence today. *This digest is prepared by OCRA (Ovarian Cancer Research Alliance) for patients, caregivers, and advocates. It is intended to inform, not to guide individual treatment decisions. Please speak with your care team about what research findings may mean for your specific situation.* --- **Sources** *Citations are grouped by the topic sections above. Within each section, the papers directly referenced in the digest are listed first, followed by additional on-topic papers published this month that are either not discussed above or are behind access restrictions.* **Sharpening How We Use PARP Inhibitors** ***Directly referenced:*** **1.** Domènech H, et al. "Comprehensive clinical cancer analysis of homologous recombination deficiency biomarkers in an academic molecular profiling program." *NPJ precision oncology.* July 11, 2026. PMID 42436298. **2.** Jiang F, et al. "Combination of Niraparib and Lapatinib for Ovarian Cancer Treatment." *Cancer research and treatment.* July 29, 2025. PMID 40744812. **3.** Miedziarek C, et al. "Preoperative PARP Inhibitors in Ovarian Cancer Trials: Connecting Molecular Oncology and Cytoreductive Surgery." *Cancers.* July 5, 2026. PMID 42449699. **4.** Liang L, et al. "Efficacy and safety of PARP inhibitors in older patients with advanced ovarian cancer: a systematic review and network meta-analysis." *Frontiers in oncology.* July 9, 2026. PMID 42494613. **5.** Martin MD, et al. "Assessing the Clinical Relevance ofRING Domain Variants of Uncertain Significance." *Current oncology (Toronto, Ont.).* July 3, 2026. PMID 42505201. ***Additional citations on related topics:*** **6.** Nguyen HT, et al. "Next-generation sequencing-based characterization of BRCA1/2 variants across multiple tumor types in Vietnamese patients." *BMC cancer.* July 17, 2026. PMID 42464142. (open access) **7.** Li NM, et al. "\[Analysis of homologous recombination deficiency testing in ovarian cancer based on next-generation sequencing\]." *Zhonghua zhong liu za zhi \[Chinese journal of oncology\].* July 23, 2026. PMID 42477931. (subscription access) **8.** Chen MY, et al. "\[Clinical and familial characterisation of ovarian cancer patients with germline mutations in thegene and the current status of prevention in high-risk groups\]." *Zhonghua zhong liu za zhi \[Chinese journal of oncology\].* July 23, 2026. PMID 42477928. (subscription access) **9.** Chaplin EH, et al. "Association Between Prior PARP Inhibitor Maintenance Therapy and Myelosuppression During Subsequent Chemotherapy in Ovarian Cancer." *The Annals of pharmacotherapy.* July 7, 2026. PMID 42411355. (subscription access) **10.** Ang BH, et al. "BRCA Testing in Asian Patients with Ovarian Cancer: Standard Clinical Practice or Mutation Prediction Model?" *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.* July 1, 2026. PMID 42013351. (subscription access) **11.** Dossa F, et al. "Breast and Ovarian Cancer Among Individuals Undergoing BRCA1 and BRCA2 Testing." *JAMA network open.* July 1, 2026. PMID 42530926. (restricted license, CC BY-NC-ND / CC BY-NC-SA) **12.** Jiao Y, et al. "Cancer risks for ATM variant heterozygotes." *Genetics in medicine : official journal of the American College of Medical Genetics.* April 28, 2026. PMID 42052916. (subscription access) **13.** Seyahian A, et al. "Chimeric antigen receptor-natural killer cell therapy in first-relapse epithelial ovarian cancer: an early health-economic evaluation in the Netherlands." *Cytotherapy.* April 3, 2026. PMID 42134093. (subscription access) **14.** Canary HE, et al. "Clinical and Family Conversations Regarding Genetic Testing: A Case Study of Uncertainty Management." *Health communication.* October 16, 2025. PMID 41102875. (subscription access) **15.** Sims TT, et al. "Correlation of BRCA and homologous recombination deficiency status with clinical and survival outcomes in patients with advanced-stage ovarian cancer undergoing frontline therapy." *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.* January 19, 2026. PMID 41680019. (subscription access) **16.** Cai P, et al. "Cost-Effectiveness of olaparib plus bevacizumab versus bevacizumab monotherapy as first-line maintenance for patients with advanced ovarian cancer: a analysis from a Chinese healthcare perspective." *Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences.* July 22, 2026. PMID 42484750. (subscription access) **17.** Jiang C, et al. "Current status and prospects of chemotherapy-free strategies in ovarian cancer." *Critical reviews in oncology/hematology.* July 17, 2026. PMID 42468792. (subscription access) **18.** Frenel JS, et al. "Deep learning-based prediction of homologous recombination deficiency from histopathological whole-slide images in ovarian cancer." *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.* April 18, 2026. PMID 42235122. (subscription access) **19.** Kitaura S, et al. "Early diagnosis of peritoneal carcinoma based on a subtle rise in serum CA125 level within the normal range in a BRCA2 mutation carrier with serous tubal intraepithelial carcinoma discovered after risk-reducing salpingo-oophorectomy: A case report and literature review." *Taiwanese journal of obstetrics & gynecology.* July 2026. PMID 42362269. (subscription access) **20.** Toyohara Y, et al. "Effect of first-line poly(ADP-ribose) polymerase inhibitor on second-line platinum-based chemotherapy in epithelial ovarian cancer." *Journal of gynecologic oncology.* March 16, 2026. PMID 41906780. (subscription access) **21.** Wu CH, et al. "Evaluating homologous recombination status and the efficacy/safety of PARP inhibitors in advanced epithelial ovarianl cancer: A single-institute preliminary experience." *Taiwanese journal of obstetrics & gynecology.* July 2026. PMID 42362262. (subscription access) **22.** Zhao CL, et al. "Folate receptor alpha, TROP2 and HER2 in high-grade serous ovarian Cancer: Expression and clinicopathological correlations." *Gynecologic oncology.* July 14, 2026. PMID 42447657. (subscription access) **23.** De Paolis E, et al. "Genomic profiling as an option for ovarian cancer diagnostics." *Expert review of molecular diagnostics.* July 21, 2026. PMID 42422928. (subscription access) **24.** Ge Y, et al. "Homologous recombination deficiency in high-grade serous ovarian carcinoma: clinical pathological characteristics, impact of neoadjuvant chemotherapy, and prognostic implications." *Journal of gynecologic oncology.* February 9, 2026. PMID 41775254. (subscription access) **25.** Schnaiter S, et al. "Homologous recombination deficiency-driven genomic instability in ovarian cancer as an indicator of BRCA1 and BRCA2 variant pathogenicity." *American journal of human genetics.* June 23, 2026. PMID 42335889. (subscription access) **26.** Macdonald CJ, et al. "Identification of novel drug-specific PARP inhibitor resistance mechanisms in ovarian cancer-implications for clinical practice." *British journal of cancer.* April 17, 2026. PMID 41998207. (subscription access) **27.** Raj AK, et al. "Immunofluorescence-Based Assay for Detection of Nuclear RAD51 Foci as a Marker of Homologous Recombination Repair in Ovarian Cancer Cells." *Journal of visualized experiments : JoVE.* July 17, 2026. PMID 42545908. (subscription access) **28.** Ono K, et al. "Impact of prior olaparib use on subsequent platinum-based therapy in recurrent ovarian cancer." *Journal of gynecologic oncology.* February 13, 2026. PMID 41796993. (subscription access) **29.** Darnold JS, et al. "Insights from three decades of BRCA1/2 modeling in mice." *Nature genetics.* January 6, 2026. PMID 41495480. (subscription access) **30.** Roa AP, et al. "Is platinum the new gold? Re-evaluating platinum's enduring role and future potential in the era of novel ovarian cancer therapies." *Journal of controlled release : official journal of the Controlled Release Society.* May 6, 2026. PMID 42103028. (subscription access) **31.** Swearingen A, et al. "Limited inclusion in clinical trials and access to PARP inhibitors in racial and ethnic minority patients with cancer: A Narrative Review." *The oncologist.* July 25, 2026. PMID 42503179. (subscription access) **32.** Cho HW, et al. "Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor." *Clinical cancer research : an official journal of the American Association for Cancer Research.* July 1, 2026. PMID 41609513. (subscription access) **33.** Widick PC, et al. "Maintenance therapy in gynecologic malignancies: Current and future state." *Cancer.* July 15, 2026. PMID 42397796. (subscription access) **34.** Chauhan R, et al. "Metronomic Chemotherapy in Ovarian Cancer: Current Scenario and AI-Integrated Future Strategies." *Cancer reports (Hoboken, N.J.).* July 2026. PMID 42432987. (subscription access) **35.** Li C, et al. "PAK1 inhibition synergistically enhances the anti-tumor efficacy of PARP inhibitors in ovarian cancers." *Genes & diseases.* October 21, 2025. PMID 42017177. (subscription access) **36.** Chao WT, et al. "PARP inhibitor maintenance takes advantages in advanced epithelial ovarian cancer but May show a negative impact while recurrence occurs: a multi-center retrospective study in Taiwan." *Journal of gynecologic oncology.* February 24, 2026. PMID 41796994. (subscription access) **37.** Roy A, et al. "Pathophysiological affair between protein kinase D and epithelial ovarian cancer: A roadmap towards translating the mechanism from bench to bedside." *Biochimica et biophysica acta. Reviews on cancer.* July 9, 2026. PMID 42425229. (subscription access) **38.** Koyama K, et al. "Prevalence and Independence of p53 Signatures and β-Catenin Signatures in Risk-Reducing Salpingo-Oophorectomy Specimens." *Pathology international.* July 2026. PMID 42482410. (subscription access) **39.** Sherigar P, et al. "Recent Advances in Genetic Testing and Clinical Management of Hereditary Breast and Ovarian Cancer (HBOC) in India." *Cancer medicine.* July 2026. PMID 42499015. (subscription access) **40.** Sachdeva M, et al. "Returning to PARP Inhibition: Rechallenge with Bevacizumab in Ovarian Cancer." *Clinical cancer research : an official journal of the American Association for Cancer Research.* July 1, 2026. PMID 42024147. (subscription access) **41.** Tsemach RG, et al. "Staying in the Unknown: Avoidance of Genetic Testing in Families With Hereditary Cancer Syndromes-A Qualitative Study." *Journal of clinical nursing.* July 29, 2026. PMID 42522722. (subscription access) **42.** Kul Karadenizli P, et al. "Synthesis and biological evaluation of 6,9-disubstituted purine analogues inducing autophagy-mediated apoptosis and potentiating carboplatin response in high-grade serous ovarian cancer." *Bioorganic chemistry.* July 1, 2026. PMID 42391813. (subscription access) **43.** Yarunin A, et al. "Technical evaluation of commercially available homologous recombination deficiency assays using MyChoice CDx as reference in ovarian cancer." *Gynecologic oncology.* June 25, 2026. PMID 42349204. (subscription access) **44.** Maradiya R, et al. "The real-world utility of homologous repair deficiency testing in BRCA1/2 wild-type high-grade serous carcinoma and the utility of MYC amplification as a potential surrogate marker." *Gynecologic oncology.* July 13, 2026. PMID 42442041. (subscription access) **45.** Liu A, et al. "UBTD1 Drives Ovarian Cancer Progression via Mutation-Associated Alterations, Stromal Microenvironment Remodeling, and TNF/AP-1 Signaling." *Human mutation.* July 22, 2026. PMID 42488496. (subscription access) **46.** Shahin MS, et al. "Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer." *Gynecologic oncology.* July 1, 2026. PMID 42385609. (subscription access) **47.** Lloyd-Ellis S, et al. "Uptake of risk-reducing medical interventions among female BRCA1/2 pathogenic variant carriers: A population-based study in British Columbia." *Gynecologic oncology.* May 21, 2026. PMID 42166900. (subscription access) **48.** Nakayama J, et al. "US real-world biomarker testing differences and treatment choice in advanced ovarian cancer: results of a retrospective study." *Future oncology (London, England).* July 16, 2026. PMID 42460506. (subscription access) **New Strategies for Platinum-Resistant Disease** ***Directly referenced:*** **49.** Wang W, et al. "Targeting glucocorticoid receptor signaling in platinum-resistant ovarian cancer: translational rationale and clinical advances following the ROSELLA trial." *Oncology reviews.* July 9, 2026. PMID 42494820. **50.** Zhao Y, et al. "Multi-Omics Profiling of High-Grade Serous Ovarian Cancer Reveals an Inflammation-Related Lipid Metabolism Subtype Associated With Platinum Resistance." *Advanced science (Weinheim, Baden-Wurttemberg, Germany).* July 17, 2026. PMID 42466711. **51.** Zhao X, et al. "A prediction model for platinum-resistant recurrence of ovarian cancer was established using multimodal artificial intelligence machine learning methods." *Frontiers in medicine.* July 8, 2026. PMID 42487970. ***Additional citations on related topics:*** **52.** Cheng L, et al. "Large-scale transcriptome analysis reveals KIF20A as a novel indicator of cisplatin resistance in high-grade serous ovarian cancer." *Journal of ovarian research.* July 9, 2026. PMID 42426841. (open access) **53.** Nagappan A, et al. "Oncogenic EGFR Signaling as a Central Regulator of Chemoresistance in Ovarian Cancer: A Mechanistic Review." *International journal of molecular sciences.* July 1, 2026. PMID 42450204. (open access) **54.** Herrera ADP, et al. "Systems-Level Mapping of the Tumor Microenvironment Reveals Immune-Mediated Mechanisms and Potential Targets in Platinum-Resistant Ovarian Cancer." *Research square.* July 22, 2026. PMID 42539139. (open access) **55.** Stasiak P, et al. "Vismodegib Exerts a Pleotropic Effect on Topotecan-Resistant and Sensitive Ovarian Cancer Cell Lines in 2D and 3D Cell Culture Models." *Molecules (Basel, Switzerland).* July 2, 2026. PMID 42451698. (open access) **56.** Chakraborty S, et al. "A kinetically inert platinum antitumor agent overcomes mutant p53-driven chemoresistance via oxidative stress-mediated DNA damage." *Medical oncology (Northwood, London, England).* July 22, 2026. PMID 42484733. (subscription access) **57.** Kim J, et al. "Antitumor efficacy of repurposed phenformin in preclinical models of epithelial ovarian cancer." *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.* July 9, 2026. PMID 42424918. (subscription access) **58.** Al-Qaysi ASA, et al. "Atranorin suppresses the LUCAT1/STAT3 axis to induce ferroptotic cell death in ovarian cancer." *Molecular biology reports.* July 24, 2026. PMID 42496762. (subscription access) **59.** Yavuz DD, et al. "Benchmarking Ultra-Low Attachment and Photopatterned GelMA 3D Culture Platforms for Modeling Cancer Stemness in High-Grade Serous Ovarian Cancer." *Biotechnology journal.* July 2026. PMID 42528220. (subscription access) **60.** Shirafkan A, et al. "Biosynthesis, characterization, and antiproliferative activity of gold nanoparticles synthesized using Artemisia chamaemelifolia extract against cisplatin-resistant ovarian cancer cells." *Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences.* July 22, 2026. PMID 42484766. (subscription access) **61.** Vuong TT, et al. "DNA Methyltransferase Inhibition Prevents Platinum-Induced Ovarian Cancer Stem Cell Enrichment." *Cancer research communications.* July 1, 2026. PMID 42361323. (subscription access) **62.** Krasny S, et al. "Elenagen, a p62/SQSTM1-encoding plasmid, improves overall survival in patients with platinum-resistant ovarian cancer: a phase II trial." *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.* January 7, 2026. PMID 41577503. (subscription access) **63.** Roering P, et al. "High expression of the multifunctional proto-oncogene BMI1 predicts poor outcome in high-grade serous carcinoma." *Cancer treatment and research communications.* July 29, 2026. PMID 42526155. (subscription access) **64.** Raies S, et al. "Liposome-based nanocarriers for Ovarian cancer: Molecular targeting, therapeutic mechanisms, and clinical translation." *Colloids and surfaces. B, Biointerfaces.* March 2, 2026. PMID 41795321. (subscription access) **65.** Tan Y, et al. "Lycorine suppresses cell growth and attenuates stemness through PI3K/AKT pathway in ovarian cancer." *Biochemical pharmacology.* March 7, 2026. PMID 41802683. (subscription access) **66.** Ye M, et al. "Patient-derived ovarian cancer organoids as platforms for predicting platinum resistance and screening tumor stem cell inhibitors." *Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.* May 6, 2026. PMID 42128460. (subscription access) **67.** Li H, et al. "Quercetin induces ferroptosis in ovarian cancer by suppressing the NRF2/HO‑1/GPX4 axis and increasing the efficacy of cisplatin." *Biochemical pharmacology.* July 15, 2026. PMID 42456829. (subscription access) **68.** Lujano-Olazaba O, et al. "RelB drives integrin-mediated stress tolerance and relapse in high-grade serous ovarian cancer." *Cell reports.* July 3, 2026. PMID 42400907. (subscription access) **69.** Ozberk U, et al. "Survival advantage of bevacizumab rechallenge in recurrent ovarian cancer regardless of platinum sensitivity." *Anti-cancer drugs.* May 6, 2026. PMID 41430637. (subscription access) **70.** Lesnock JL, et al. "Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0." *Journal of clinical oncology : official journal of the American Society of Clinical Oncology.* July 13, 2026. PMID 42441925. (subscription access) **71.** Deng W, et al. "The role of reactive oxygen species metabolism-related genes in mediating cisplatin resistance in ovarian clear cell carcinoma." *JPMA. The Journal of the Pakistan Medical Association.* July 2026. PMID 42444226. (subscription access) **Immunotherapy and Targeted Therapy: Progress on a Historically Hard Problem** ***Directly referenced:*** **72.** Sweis RF, et al. "Phase 1/2 study of IMC-C103C, a T cell receptor bispecific (MAGE-A4×CD3) ImmTAC targeting MAGE-A4-expressing malignancies." *Journal for immunotherapy of cancer.* July 20, 2026. PMID 42476725. **73.** Scholler J, et al. "Engineering a juxtamembrane-targeting CAR T-cell against mesothelin: a novel binder resilient to shed antigen for enhanced efficacy against ovarian and pancreatic cancer." *Frontiers in immunology.* July 1, 2026. PMID 42459653. **74.** Beziaud L, et al. "Reversal of T cell exhaustion enables cancer vaccine efficacy in-deficient ovarian cancer." *iScience.* June 30, 2026. PMID 42491848. **75.** Faradina D, et al. "The promising role of engineered T lymphocytes in immunotherapy for high-grade serous ovarian carcinoma: a review of mechanisms, clinical landscape, and future strategies." *Journal of the Egyptian National Cancer Institute.* July 27, 2026. PMID 42507306. **76.** Yen TT, et al. "Immunotherapy and Relevant Antibody-Drug Conjugates in Gynecologic Oncology: Recent Advances, Ongoing Challenges, and Future Directions." *Cancers.* July 20, 2026. PMID 42512405. **77.** Salinaro J, et al. "Association between HER2 expression, genomic characteristics, and tumor immune microenvironment dynamics in epithelial ovarian cancer." *Frontiers in oncology.* July 20, 2026. PMID 42548619. ***Additional citations on related topics:*** **78.** Bai Y, et al. "A CAF-Associated Stromal Remodeling Signature Links Immune Exclusion to Exhaustion-Prone CD8T-Cell Dysfunction in High-Grade Serous Ovarian Cancer." *International journal of molecular sciences.* July 7, 2026. PMID 42450357. (open access) **79.** Chauvin M, et al. "Cancer-associated mesothelial cells drive immune escape and therapy resistance in ovarian cancer." *Journal for immunotherapy of cancer.* July 30, 2026. PMID 42532631. (open access) **80.** Steindl-Tomschizek T, et al. "Case Report: Durable response to mirvetuximab soravtansine in a patient with platinum-sensitive ovarian cancer and a diagnosis of myelodysplastic syndrome." *Frontiers in oncology.* July 9, 2026. PMID 42494605. (open access) **81.** Xu Y, et al. "CD73-LNPs promote antitumor T-cell immunity via amplifying TLR3-mediated immunostimulatory dendritic cell activation." *Journal of translational medicine.* July 21, 2026. PMID 42482149. (open access) **82.** Zhou X, et al. "Dual-block HER2 assessment reveals clinically relevant intratumoral heterogeneity in gynecologic cancers: a single-center landscape analysis." *Journal of translational medicine.* July 3, 2026. PMID 42399958. (open access) **83.** Onuma T, et al. "Natural Killer Cell Plasticity in Epithelial Ovarian Cancer and Their Therapeutic Implications." *Cells.* July 9, 2026. PMID 42505353. (open access) **84.** Zidi S, et al. "PDCD1 gene polymorphisms linked with altered risk of female-specific hormone-dependent cancers: a systematic review and meta-analysis." *BMC cancer.* July 1, 2026. PMID 42387483. (open access) **85.** Grubišić DA, et al. "Prognostic Value of Morphological Characteristics and Immune Microenvironment in High-Grade Serous Cancer (HGSC)." *Cancers.* July 19, 2026. PMID 42512390. (open access) **86.** Jiang F, et al. "Advances in current and emerging immunotherapies for ovarian cancer." *Critical reviews in oncology/hematology.* April 7, 2026. PMID 41956332. (subscription access) **87.** Ciliberti E, et al. "Antibody drug conjugates in gynaecological cancers: navigating between opportunities and challenges." *EClinicalMedicine.* June 15, 2026. PMID 42534594. (subscription access) **88.** El Hajj H, et al. "Best original research presented at the 27th European Congress on Gynaecological Oncology: best of ESGO 2026." *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.* July 11, 2026. PMID 42541943. (subscription access) **89.** Zhang B, et al. "Blockade of co-inhibitory receptor immune checkpoint protein TIM3/CD366 augments the anti-cancer activity of CAR-T therapy in solid tumors: An ovarian cancer example." *Genes & diseases.* December 11, 2025. PMID 42004220. (subscription access) **90.** Bashi AC, et al. "Capivasertib Combines with Trastuzumab Deruxtecan to Enhance Antitumor Activity in HER2-Positive and HER2-Low Tumors." *Molecular cancer therapeutics.* July 2, 2026. PMID 41789558. (subscription access) **91.** Ottum S, et al. "Claudin-6 as a potential target in the treatment of ovarian cancer: a review of emerging drugs." *Expert opinion on emerging drugs.* July 26, 2026. PMID 42466859. (subscription access) **92.** Liu V, et al. "Clonal lineage tracing of innate immune cells in human cancer." *Cancer cell.* June 4, 2026. PMID 42242233. (subscription access) **93.** Gahbauer S, et al. "EGFRxCD16 bispecific antibodies orchestrate superior NK cell-mediated lysis of ovarian cancer and NSCLC cell lines in combination with oncolytic viruses." *Cancer immunology, immunotherapy : CII.* July 3, 2026. PMID 42397418. (subscription access) **94.** Wang Q, et al. "Emerging treatment paradigms for gastric cancer peritoneal metastasis in the era of multimodal precision therapy." *Critical reviews in oncology/hematology.* April 27, 2026. PMID 42055237. (subscription access) **95.** Xu Y, et al. "GLT8D2-mediated PD-L1 N-glycosylation promotes tumor immune evasion in ovarian cancer peritoneal metastasis." *Cancer letters.* April 3, 2026. PMID 41936856. (subscription access) **96.** Wang R, et al. "High-Density Wild-Type IL-2 Nanoparticles Preferentially Enhance CD8⁺ T-Cell Expansion and Reprogram the Tumor Microenvironment." *bioRxiv : the preprint server for biology.* July 15, 2026. PMID 42523311. (subscription access) **97.** Lee YJ, et al. "Histology-specific ADC target landscapes in ovarian cancer and therapy-associated antigen downshift after ADC exposure." *Gynecologic oncology.* June 3, 2026. PMID 42235136. (subscription access) **98.** Lin SY, et al. "Human epidermal growth factor receptor-2, nectin-4, and trophoblast cell surface antigen-2 expression varies significantly across ovarian cancer histotypes." *Taiwanese journal of obstetrics & gynecology.* July 2026. PMID 42362263. (subscription access) **99.** Tang Q, et al. "Human NKG2Cadaptive NK cells for Cancer immunotherapy." *International immunopharmacology.* July 18, 2026. PMID 42470855. (subscription access) **100.** Heidinger M, et al. "Immunotherapy advancements in high-grade serous ovarian cancer: From promise to practice." *Critical reviews in oncology/hematology.* April 1, 2026. PMID 41933852. (subscription access) **101.** Flint ML, et al. "Incidence and clinical features of cataracts: an under-recognized adverse event with mirvetuximab soravtansine-gynx in ovarian cancer." *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.* April 25, 2026. PMID 42172956. (subscription access) **102.** Stirblyte K, et al. "Lipid metabolism in γδ T-cell activation: Implications for immunotherapy in ovarian cancer." *Translational oncology.* July 27, 2026. PMID 42520474. (subscription access) **103.** Wang T, et al. "LOX-1 mediated lipid peroxidation leads to dysfunction of tumor infiltrating CD8T cells in ovarian cancer." *Redox biology.* July 20, 2026. PMID 42537477. (subscription access) **104.** Prasad A, et al. "Mitochondrial metabolic vulnerabilities in high-grade serous ovarian cancer." *Biochimica et biophysica acta. Reviews on cancer.* March 7, 2026. PMID 41802549. (subscription access) **105.** Cheng Y, et al. "Nanocrystalline berberine is associated with improved antitumor activity of PD-1 blockade in ovarian cancer." *Phytomedicine : international journal of phytotherapy and phytopharmacology.* April 19, 2026. PMID 42096996. (subscription access) **106.** Zhang Z, et al. "Neoadjuvant tislelizumab (anti-PD-1 antibody) plus chemotherapy in patients with advanced epithelial ovarian cancer: the exploratory NAIVE trial." *Signal transduction and targeted therapy.* July 3, 2026. PMID 42399240. (subscription access) **107.** Pandraklakis A, et al. "Primary ovarian malignant melanoma: A systematic review of cases and pooled analysis." *Gynecologic oncology.* June 1, 2026. PMID 42224890. (subscription access) **108.** Chaturvedi A, et al. "Programmed death ligand-1 (PD-L1) expression in serous ovarian carcinoma with clinicopathological associations." *The Indian journal of medical research.* July 2026. PMID 42397824. (restricted license, CC BY-NC-ND / CC BY-NC-SA) **109.** Sun Z, et al. "Syringeable hyaluronic acid-based hydrogel co-loaded with Cisplatin and MSA-2 for enhanced ovarian cancer chemoimmunotherapy." *Biomedical materials (Bristol, England).* July 15, 2026. PMID 42456758. (subscription access) **110.** Liu Y, et al. "Treatment Sequencing in Platinum-Resistant Epithelial Ovarian Cancer After MIRASOL, KEYNOTE-B96, and ROSELLA." *International journal of women's health.* July 10, 2026. PMID 42453787. (subscription access) **111.** Ruan Y, et al. "Utilizing Single-Cell and Transcriptomic Data to Identify Mitochondrial Pathway-Associated Prognostic Genes and Their Regulatory Mechanisms of Action in Ovarian Cancer." *FASEB journal : official publication of the Federation of American Societies for Experimental Biology.* July 15, 2026. PMID 42387880. (subscription access) **112.** Lawn S, et al. "ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile." *Clinical cancer research : an official journal of the American Association for Cancer Research.* July 1, 2026. PMID 42007996. (subscription access) **Toward Earlier Detection** ***Directly referenced:*** **113.** Wang L, et al. "Transcriptomic analysis of tissue-resident memory T cells of the fallopian tube reveals a precursor immune surveillance network for ovarian cancer prevention." *Nature communications.* July 13, 2026. PMID 42443174. **114.** Baspinar SN, et al. "Serum miR-181a-5p, miR-214-3p, and miR-223-3p in epithelial ovarian cancer." *Scientific reports.* July 6, 2026. PMID 42409933. **115.** Guo Q, et al. "Ovarian Cancer Diagnosis and Chemoresistance Prediction Model Based on cfRNA Molecular Signature." *Advanced science (Weinheim, Baden-Wurttemberg, Germany).* July 17, 2026. PMID 42467997. **116.** Chen P, et al. "Integrating structurally defined DNA-carbon nanotube sensors with machine learning for cancer detection." *Science advances.* July 29, 2026. PMID 42525763. **117.** Moise-Crintea A, et al. "Nanotechnology in Ovarian Cancer: Advances in Early Diagnosis and Targeted Therapy to Enhance Patient Quality of Life." *Cells.* July 10, 2026. PMID 42505358. ***Additional citations on related topics:*** **118.** Kozłowski M, et al. "DNA Methylation and mRNA Expression of SEPT9 and AKR1B1 in Ovarian Cancer: Diagnostic and Prognostic Implications." *International journal of molecular sciences.* July 16, 2026. PMID 42511679. (open access) **119.** Zhu J, et al. "\[Medical prior-guided TabMap deep learning model for ovarian cancer prediction and interpretability analysis\]." *Nan fang yi ke da xue xue bao = Journal of Southern Medical University.* July 20, 2026. PMID 42486839. (subscription access) **120.** Gu Y, et al. "A diagnostic nomogram model integrating the ultrasound ovarian-adnexal reporting and data system and serum indexes for predicting malignancy in patients with ovarian masses." *The British journal of radiology.* July 1, 2026. PMID 42024575. (subscription access) **121.** Dawes K, et al. "A DNA Methylation-based algorithm Improves Lung Cancer risk prediction in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial." *Lung cancer (Amsterdam, Netherlands).* May 18, 2026. PMID 42167026. (subscription access) **122.** Jiang Y, et al. "A hybrid membrane-camouflaged CuS nanoplatform for synergistic nanotherapy of ovarian cancerchemodynamic and sonodynamic effects." *Journal of materials chemistry. B.* July 8, 2026. PMID 42305079. (subscription access) **123.** Tuan NQ, et al. "A Nomogram for Preoperative Prediction of Ovarian Cancer Risk: A Single-Center Study from Vietnam." *La Clinica terapeutica.* 2026. PMID 42340783. (subscription access) **124.** Zhang S, et al. "A Novel Approach to Ovarian Cancer Diagnosis via CT Imaging: GPT-4o-Driven Automated Feature Recognition and Validation in Clinical Settings." *Annals of surgical oncology.* February 17, 2026. PMID 41703208. (subscription access) **125.** Funk AM, et al. "A Urinary Three-Metabolite Signature Enables Noninvasive Identification of Patients with High-Risk Ovarian Cancer." *Clinical cancer research : an official journal of the American Association for Cancer Research.* July 17, 2026. PMID 42029478. (subscription access) **126.** Wang Y, et al. "Applications of Large Language Models in Ovarian Cancer Management: Protocol for a Systematic Review and Meta-Analysis." *JMIR research protocols.* July 10, 2026. PMID 42430510. (subscription access) **127.** Guo Y, et al. "Automated O-RADS Risk Stratification Using a Large Language Model Analysis of Narrative Ultrasound Reports." *Ultrasound in medicine & biology.* April 11, 2026. PMID 41966937. (subscription access) **128.** Wang L, et al. "Bilateral highly differentiated follicular carcinoma of ovarian origin with extensive abdominal metastasis: A case report." *Medicine.* July 17, 2026. PMID 42470065. (subscription access) **129.** Erdoğan ÖŞ, et al. "Blood-based RBBP7 and RIBC1 methylation as a candidate epigenetic biomarker for ovarian cancer epigenetic markers RBBP7 and RIBC1 in ovarian cancer." *Molecular biology reports.* July 29, 2026. PMID 42525292. (subscription access) **130.** Luo M, et al. "Breaking the "Whack-a-Mole" Dilemma in Cancer Therapy: Ultrasound-Propelled ROS Storm Enables Triple-Modal Cell Death." *Small (Weinheim an der Bergstrasse, Germany).* May 15, 2026. PMID 42138032. (subscription access) **131.** Shan Y, et al. "Clinicopathologic spectrum and outcomes of primary ovarian lymphoma: a retrospective case series." *Leukemia & lymphoma.* June 7, 2026. PMID 42251697. (subscription access) **132.** Akonde M, et al. "Correlates of Serum Concentrations of Biomarkers Relevant to Ovarian Cancer Screening." *The journal of applied laboratory medicine.* July 1, 2026. PMID 42018468. (subscription access) **133.** Zhao N, et al. "Development and diagnostic performance of a modified O-RADS model incorporating septa number and blood flow for adnexal lesions." *Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.* July 31, 2026. PMID 42536923. (subscription access) **134.** Jeong S, et al. "Enhanced ovarian cancer diagnosis using deep learning on pelvic ultrasound with integrated clinical data: retrospective multicenter study." *Journal of gynecologic oncology.* March 19, 2026. PMID 41906782. (subscription access) **135.** Zhang Q, et al. "From structural complexity to causal representation: A dynamic fractal-attention framework for fine-grained ovarian tumor classification in ultrasound." *Medical image analysis.* April 24, 2026. PMID 42035560. (subscription access) **136.** Lof P, et al. "Human epididymis protein 4 and risk of malignancy index as risk assessment tools in the decision for referral to an oncology center in patients with an ovarian mass: a cost-effectiveness analysis from a Dutch health care perspective." *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.* April 22, 2026. PMID 42275792. (subscription access) **137.** El Desoky AMZ, et al. "lncRNA MEG3 and Beclin-1 as diagnostic biomarkers in serous ovarian carcinoma: molecular and immunohistochemical insights." *Journal of molecular histology.* July 14, 2026. PMID 42446766. (subscription access) **138.** Gao Y, et al. "Non-invasive screening for ovarian cancer by combining serum SERS with interpretable machine learning models." *Talanta.* February 19, 2026. PMID 41724105. (subscription access) **139.** Viesca EL, et al. "Ovarian Sclerosing Stromal Tumor. Spectrum of Ultrasound Findings. A Case Report and Review of Literature." *Journal of clinical ultrasound : JCU.* February 25, 2026. PMID 41741234. (subscription access) **140.** Dueholm Hjorth IM, et al. "Prospective external validation of ADNEX and RMI for estimating risk of malignancy in adnexal masses in general gynecological settings: Danish multicenter study." *Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.* July 9, 2026. PMID 42425520. (subscription access) **141.** Si J, et al. "Single-Cell-Derived Malignant Epithelial Programs Define Prognostic Risk and Therapeutic Vulnerability in Ovarian Cancer." *Journal of Cancer.* July 3, 2026. PMID 42524312. (subscription access) **142.** Liu S, et al. "The diagnostic value of \[F\]F-NOTA-FAPI PET/CT in suspected recurrent ovarian cancer with CA125 dynamic increase level but negative conventional imaging findings." *European journal of nuclear medicine and molecular imaging.* March 18, 2026. PMID 41848875. (subscription access) **143.** Kawaguchi R, et al. "Tissue Factor Pathway Inhibitor-2 (TFPI2) as a Biomarker in Gynecologic Malignancies: A Narrative Review Focusing on Clear Cell Carcinoma." *The journal of obstetrics and gynaecology research.* July 2026. PMID 42349846. (subscription access) **144.** Koyama K, et al. "Tubal epithelial alterations: evolving concepts." *Journal of gynecologic oncology.* May 27, 2026. PMID 42252253. (subscription access) **145.** Subramani K, et al. "Tubal ligation exacerbates ovulation-driven TP53 mutagenesis and p53 signatures by depleting protective menstrual hemoglobin." *The Journal of pathology.* April 29, 2026. PMID 42052633. (subscription access) **146.** Funston G, et al. "Using large language models to identify prediagnostic clinical features of ovarian cancer from healthcare records: a population-based case-control study." *The British journal of general practice : the journal of the Royal College of General Practitioners.* June 25, 2026. PMID 42055579. (subscription access) **Surgery: Advances and Safety** ***Directly referenced:*** **147.** Bae J, et al. "Hybrid surgical approach for advanced ovarian cancer: hybrid approach for robotic and minimal open abdominal cytoreduction technique." *Obstetrics & gynecology science.* June 30, 2026. PMID 42375098. **148.** Purwar R, et al. "Anatomical precision in the omics era: a proposed framework for selective para-aortic lymphadenectomy in epithelial ovarian cancer." *Frontiers in medicine.* July 8, 2026. PMID 42487951. **149.** Wang Y, et al. "The incidence and risk factors of sepsis following ovarian cancer surgery: A retrospective Nationwide Inpatient Sample database study." *PloS one.* July 20, 2026. PMID 42475320. ***Additional citations on related topics:*** **150.** Ege G, et al. "The predictive value of Hemoglobin-Albumin-Lymphocyte-Platelet score for maximal cytoreduction surgery in advanced-stage epithelial ovarian cancer." *Revista da Associacao Medica Brasileira (1992).* July 10, 2026. PMID 42454842. (open access) **151.** Kong TW, et al. "A multicenter study of laparoscopic versus laparotomic surgery in the treatment of stage I adult granulosa cell and Sertoli-Leydig cell tumors: (LARGES): Gynecologic Oncology Research Investigators coLLaborAtion study (GORILLA-3005)." *Gynecologic oncology.* June 4, 2026. PMID 42242177. (subscription access) **152.** Gaillard S, et al. "Atezolizumab in combination with neoadjuvant chemotherapy and interval cytoreductive surgery for patients with newly diagnosed advanced-stage epithelial ovarian cancer: the AdORN study." *Gynecologic oncology.* June 12, 2026. PMID 42284713. (subscription access) **153.** Corbaux P, et al. "Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trial." *Translational oncology.* July 1, 2026. PMID 42385345. (subscription access) **154.** Sinukumar S, et al. "Ca125 KELIM as a Potential Tool for Predicting Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Benefit at Interval Cytoreductive Surgery for Advanced Epithelial Ovarian Cancer-A Propensity Score-Matched Analysis." *Journal of surgical oncology.* April 27, 2026. PMID 42045801. (subscription access) **155.** Machuca-Aguado J, et al. "Clinical relevance of the characterisation and quantification of CD8+ T-cell infiltration in high-grade serous ovarian carcinoma using machine learning-based image analysis of dual immunostaining." *Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia.* April 11, 2026. PMID 41966548. (subscription access) **156.** Huvila J, et al. "Coexistent Endometrial and Ovarian Carcinoma: Terminology, Clinicopathological Features, and Clinical Significance." *International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.* April 21, 2026. PMID 42011770. (subscription access) **157.** Dorri NM, et al. "Could systematic ileostomy decrease anastomotic leakage after modified posterior exenteration in advanced stage ovarian cancer patients? retrospective cohort analysis of two referral centers." *European journal of obstetrics, gynecology, and reproductive biology.* April 22, 2026. PMID 42061050. (subscription access) **158.** Ohm N, et al. "CT-derived body composition and clinical outcomes in ovarian cancer patients: A scoping review." *European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.* May 19, 2026. PMID 42184663. (subscription access) **159.** Ribero L, et al. "Defining surgical fitness in advanced ovarian cancer: a critical review of predictors, algorithms, and pre-habilitation." *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.* April 30, 2026. PMID 42167107. (subscription access) **160.** Lin WH, et al. "Different managements of the same disease- malignant ovarian germ cell tumor treated by pediatric or gynecologic oncologists." *Taiwanese journal of obstetrics & gynecology.* July 2026. PMID 42362259. (subscription access) **161.** Siegler Y, et al. "Divide-and-Resect: A Two-Piece Infra-Colic Omentectomy Technique." *Journal of minimally invasive gynecology.* February 26, 2026. PMID 41763643. (subscription access) **162.** Tinoco NJ, et al. "Experience of surgical management of ovarian masses in pediatrics in two pediatric hospitals in the city of Bogotá between 2019-2024." *Cirugia pediatrica : organo oficial de la Sociedad Espanola de Cirugia Pediatrica.* July 20, 2026. PMID 42487424. (subscription access) **163.** Carbonell-Morote S, et al. "Futility in patients with peritoneal carcinomatosis of ovarian origin undergoing or who underwent interval cytoreductive surgery: a multicenter retrospective observational study." *Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.* February 4, 2026. PMID 41637003. (subscription access) **164.** Descargues P, et al. "Identifying patients with apparent early-stage ovarian cancer at very low risk of lymph node metastasis: a multicenter preoperative prediction model." *European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.* May 12, 2026. PMID 42127607. (subscription access) **165.** Runnebaum IB, et al. "Ileocecal and Small Bowel Involvement Are Independently Associated with Inferior Survival Despite Complete Cytoreduction in FIGO IIIC-IV Tubo-Ovarian and Primary Peritoneal Carcinoma." *Annals of surgical oncology.* April 12, 2026. PMID 41968232. (subscription access) **166.** Bou Zerdan M, et al. "Incidence of Ovarian Metastases in Reproductive-Aged Women with Appendiceal Cancer: Implications for Fertility Preservation." *Annals of surgical oncology.* July 30, 2026. PMID 42533253. (subscription access) **167.** Langstraat CL, et al. "Innovation through standardization: Reducing the ileostomy rates while targeting zero anastomotic leaks at cytoreductive surgery." *Gynecologic oncology.* May 22, 2026. PMID 42172993. (subscription access) **168.** Rose PG, et al. "Interval versus primary cytoreductive surgery in BRCA-mutated advanced-stage ovarian/peritoneal/tubal carcinoma." *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.* December 31, 2025. PMID 41672865. (subscription access) **169.** Tjokroprawiro BA, et al. "Low-grade serous ovarian cancer in Indonesia: Insights from the largest multicenter cohort in a middle-income country." *Molecular and clinical oncology.* July 8, 2026. PMID 42487878. (subscription access) **170.** Lin W, et al. "Malignant struma ovarii: Advances in molecular pathogenesis, classification, diagnosis and treatment." *Histopathology.* February 12, 2026. PMID 41684192. (subscription access) **171.** Deng J, et al. "Metabolic Syndrome Predicts Chemotherapy Resistance and Poor Prognosis in Epithelial Ovarian Cancer: A Retrospective Observational Cohort Study." *International journal of women's health.* July 9, 2026. PMID 42445369. (subscription access) **172.** Wang H, et al. "Misdiagnosis of Endometrioid Borderline Ovarian Tumors by Intraoperative Frozen Section Pathology: A Case Report and Review of the Literature." *The American journal of case reports.* July 8, 2026. PMID 42418389. (restricted license, CC BY-NC-ND / CC BY-NC-SA) **173.** Smick AH, et al. "Molecular and spatial differences in the tumor microenvironment of high-grade serous ovarian cancers with short versus long-term survival." *Gynecologic oncology.* May 23, 2026. PMID 42176362. (subscription access) **174.** Borčinová M, et al. "Multimodal prehabilitation in patients with advanced ovarian cancer." *Gynecologic oncology.* May 19, 2026. PMID 42155563. (subscription access) **175.** Elderfield C, et al. "Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced epithelial ovarian cancer." *The Cochrane database of systematic reviews.* July 29, 2026. PMID 42522792. (subscription access) **176.** Wang D, et al. "Oncology and Fertility Outcomes for Patients with Stage IC Adult Granulosa Cell Tumor of the Ovary." *Annals of surgical oncology.* March 10, 2026. PMID 41806114. (subscription access) **177.** Kajiyama H, et al. "Ovarian Epithelioid Tumor With FUS::CREM Fusion in a 63-Year-Old Woman: A Case Report of an Emerging Entity Associated With Systemic Inflammation." *International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.* October 2, 2025. PMID 41212944. (subscription access) **178.** Zhao C, et al. "Perioperative dynamics of siglec-15 and soluble PD-L1 in ovarian cancer surgery: Influence of anaesthetic technique on immune regulation." *African journal of reproductive health.* July 15, 2026. PMID 42454331. (subscription access) **179.** Kumar M, et al. "Pregnancy-Associated Small Cell Carcinoma of the Ovary, Hypercalcaemic Type Initially Misdiagnosed as Granulosa Cell Tumour: Diagnostic Pitfalls, Treatment Challenges, and Molecular Confirmation by Next-Generation Sequencing." *Cancer reports (Hoboken, N.J.).* July 2026. PMID 42463449. (subscription access) **180.** Sao CH, et al. "Real-time intraoperative identification of malignant ovarian tumors using deep learning of clinical gross specimen images." *Taiwanese journal of obstetrics & gynecology.* July 2026. PMID 42362266. (subscription access) **181.** Lot Aronson S, et al. "Real-world use and outcomes of hyperthermic intra-peritoneal chemotherapy for stage III ovarian cancer." *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.* January 21, 2026. PMID 41723064. (subscription access) **182.** Chen J, et al. "Recurrence patterns and survival outcomes following lymphadenectomy in epithelial ovarian cancer: The impact of lymph node involvement." *Taiwanese journal of obstetrics & gynecology.* July 2026. PMID 42362261. (subscription access) **183.** Levin G, et al. "Robotic vs laparoscopic interval cytoreductive surgery in stage III ovarian cancer: an analysis of the National Cancer Database." *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.* May 21, 2026. PMID 42302709. (subscription access) **184.** Imperio-Onglao R, et al. "Sentinel Lymph Node Biopsy for Gynecologic Cancers." *Obstetrical & gynecological survey.* July 6, 2026. PMID 42406983. (subscription access) **185.** Garkhail P, et al. "Survival in advanced-staged ovarian cancer treated without cytoreductive surgery-a systematic review and exploratory meta-analysis." *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.* January 20, 2026. PMID 41690828. (subscription access) **186.** Neumann E, et al. "Targeting primary and metastatic ovarian cancer with a peptide derived from the human NAF-1/CISD2 protein." *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.* June 8, 2026. PMID 42259134. (subscription access) **187.** Chan V, et al. "Temporal Immune and Metabolic Shifts Drive the Anti-Tumor Efficacy of Resiquimod-Loaded Nanoparticles in Peritoneal Carcinomatosis." *Advanced healthcare materials.* July 8, 2026. PMID 42421168. (subscription access) **188.** Lago V, et al. "Validation of the Sentinel Lymph Node Technique in Early-stage Ovarian Cancer (SENTOV II)." *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.* November 21, 2025. PMID 41763980. (subscription access) **Diet, Environment, and the Body During Treatment** ***Directly referenced:*** **189.** Walker AR, et al. "Medically Assisted Reproduction and Hormone-Related Cancers." *JAMA network open.* July 1, 2026. PMID 42440318. **190.** Lasek I, et al. "DASH, Mediterranean, and Plant-Based Diets and Cancer Risk in Women: A Narrative Review Based on Diet Quality Indices." *Nutrients.* July 3, 2026. PMID 42451156. **191.** Ajana R, et al. "Time-Dependent Effects of PFAS and Their Mixtures on Ovarian Epithelial Cell Proliferation and Chemotherapeutic Response." *International journal of molecular sciences.* July 15, 2026. PMID 42511644. **192.** Shi W, et al. "Chemotherapy-driven gut microbiota remodeling in ovarian cancer: a prospective longitudinal study." *Journal of translational medicine.* July 29, 2026. PMID 42552537. ***Additional citations on related topics:*** **193.** Chess I, et al. ""I was in the driver's seat": A qualitative analysis of factors promoting and delaying previvors' oophorectomy after risk-reducing salpingectomy." *Gynecologic oncology.* July 15, 2026. PMID 42456483. (subscription access) **194.** Pan W, et al. "Attitudes and Experiences of Patients Diagnosed With Ovarian Cancer During Chemotherapy: A Qualitative Systematic Review." *Public health nursing (Boston, Mass.).* March 6, 2026. PMID 41789837. (subscription access) **195.** Yu C, et al. "Causal assessment of 187 dietary habits with ovarian cancer from multiple sources via Mendelian randomization and meta-analysis." *Medicine.* July 17, 2026. PMID 42469968. (subscription access) **196.** Ma C, et al. "Configurational Paths of Depression and Anxiety Symptoms in Ovarian Cancer Patients: A Fuzzy-Set Qualitative Comparative Analysis." *Depression and anxiety.* July 18, 2026. PMID 42472091. (subscription access) **197.** da Silva-Filho AL, et al. "Menopausal hormone therapy and comprehensive postmenopausal care in gynecologic cancer survivors: A position paper from the FIGO Committee on Women at Menopausal Age." *International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.* July 22, 2026. PMID 42483786. (subscription access) **198.** Sakaguchi-Mukaida H, et al. "Metabolome analysis identified exogenous cholesterol within lipid rafts that activate the Akt/mTOR signaling pathway in epithelial ovarian cancer." *International journal of cancer.* February 26, 2026. PMID 41748499. (subscription access) **199.** Barretina-Ginesta MP, et al. "Multidisciplinary management of advanced ovarian cancer in Spain: expert recommendations for achieving maximum survival and improving patient care." *Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.* July 6, 2026. PMID 42410276. (subscription access) **200.** Lu KH, et al. "Patient-Centered Approach to Surgical Prevention of Ovarian Cancer: A Nonrandomized Clinical Trial." *JAMA network open.* July 1, 2026. PMID 42412428. (subscription access) **201.** Tang X, et al. "Psychometric evaluation of the NFOSI-18 disease related symptoms - Physical, NFOSI-18 Total, and FACT GP5 in the recurrent ovarian cancer phase III study GY004." *Gynecologic oncology.* June 8, 2026. PMID 42258989. (subscription access) **202.** Li Q, et al. "Soluble TREM2 engages cell-surface nucleolin to drive vascular permeability and malignant ascites in ovarian cancer." *EMBO molecular medicine.* May 26, 2026. PMID 42192204. (subscription access) **Epidemiology, Access & Health Disparities Research** ***Additional citations on related topics:*** **203.** Qin K, et al. "Association between pelvic inflammatory disease and ovarian cancer: A bidirectional Mendelian randomization study." *Medicine.* July 24, 2026. PMID 42499052. (subscription access) **204.** Jiang Y, et al. "Comprehensive assessment of incidence, mortality, and lifetime risk of ovarian cancer: a global study with forecasts to 2050." *Journal of gynecologic oncology.* February 24, 2026. PMID 41834412. (subscription access) **205.** Zachou G, et al. "Determinants and outcomes of ovarian cancer diagnosis following an emergency presentation: a systematic review." *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.* January 19, 2026. PMID 41680020. (subscription access) **206.** Ma K, et al. "Global burden, temporal trends and cross-national inequalities of the comorbidity between depressive disorder and hormone-dependent tumors in women of reproductive ages from 1990 to 2021: A population-based analysis with projections to 2036." *Journal of affective disorders.* March 16, 2026. PMID 41850613. (subscription access) **207.** Tino AB, et al. "Knowledge and perceptions of gynaecological cancers of Pacific women in Aotearoa New Zealand." *The New Zealand medical journal.* July 17, 2026. PMID 42462231. (subscription access) **208.** Gonçalves E, et al. "Second primary cancers among females with a first primary cervical, uterine and ovarian cancer: a population-based study in North Portugal." *Cancer causes & control : CCC.* July 28, 2026. PMID 42518015. (subscription access) **209.** Mulugeta C, et al. "Survival Patterns of Patients with Ovarian Cancer in Africa: Systematic Review and Meta-analysis." *Annals of surgical oncology.* March 18, 2026. PMID 41851518. (subscription access) **210.** Bae J, et al. "Treatment patterns and survival outcomes according to histologic subtype in malignant ovarian germ cell tumors: a nationwide real-world cohort study." *Journal of gynecologic oncology.* February 2, 2026. PMID 41775250. (subscription access) **211.** Huang S, et al. "Trends and disparities in ovarian cancer incidence and mortality in the United States, 1999 to 2023: A population-based ecological trend analysis." *Medicine.* July 24, 2026. PMID 42499085. (subscription access) **General & Basic-Science Research** ***Additional citations on related topics:*** **212.** Ito Y, et al. "Clotrimazole Targets the c-Myc-Survivin Axis to Reduce the Viability of Ovarian Cancer Stem Cells Alone and in Combination with Chemotherapeutic Agents." *International journal of molecular sciences.* July 10, 2026. PMID 42511518. (open access) **213.** Yıldırım Ş, et al. "Frequency and clinicopathological features of somatic neoplasms arising in ovarian mature teratomas: a single-center experience." *Pathology oncology research : POR.* July 10, 2026. PMID 42500623. (open access) **214.** Abolghasemzade S, et al. "Hyperwrinkling of the nuclear lamina is associated with attenuated mechanosensitivity in giant nucleated cancer cells." *Science advances.* July 17, 2026. PMID 42467792. (open access) **215.** Wang Y, et al. "Integrated Single-Cell and Bulk Transcriptomic Analyses Identify a B Cell- and Plasma Cell-Associated Prognostic Signature and a Candidate Tumor-Suppressive Role forin Ovarian Cancer." *Genes.* July 8, 2026. PMID 42510824. (open access) **216.** Mandal G, et al. "Isotype-switched antibodies originating from tertiary lymphoid structures can antagonize ovarian cancer progression." *iScience.* July 10, 2026. PMID 42472098. (open access) **217.** Heidarzadeh-Pilehrood R, et al. "Machine Learning-Guided Multi-Cohort Transcriptomic Profiling Identifiesandas Diagnostic and Prognostic Biomarkers Linked to the Immune Microenvironment in High-Grade Serous Carcinoma." *International journal of molecular sciences.* July 14, 2026. PMID 42511606. (open access) **218.** Zhou X, et al. "Safety evaluation of bleomycin in ovarian cancer treatment: A pharmacovigilance analysis using Food and Drug Administration adverse event reporting system data." *The Journal of international medical research.* July 20, 2026. PMID 42478093. (open access) **219.** Godbole N, et al. "Scalable Engineering of Bio-Manufactured Extracellular Vesicles for Selective Delivery in Ovarian Cancer Patient-Derived Models." *Advanced science (Weinheim, Baden-Wurttemberg, Germany).* April 23, 2026. PMID 42023984. (open access) **220.** Hamouda RA, et al. "Silver-LoadedOil Nanoemulsions: Antimicrobial and Anticancer Potential Revealed Through In Vitro Assays and Molecular Docking." *Marine drugs.* July 13, 2026. PMID 42505984. (open access) **221.** Li R, et al. "Single-cell and spatial profiling reveal an IL-10-associated iCAF-M2 macrophage communication axis in high-grade serous ovarian cancer ascites." *Frontiers in immunology.* July 10, 2026. PMID 42500684. (open access) **222.** Huang F, et al. "Single-cell transcriptome analysis in ovarian steroid cell tumors-not otherwise specified." *Journal of ovarian research.* July 17, 2026. PMID 42469914. (open access) **223.** Zhu Y, et al. "Structure-guided discovery and evaluation of an EGFR L858R-targeting peptide with antiproliferative activity against ovarian cancer cells." *Journal of enzyme inhibition and medicinal chemistry.* July 4, 2026. PMID 42400372. (open access) **224.** Hameed SA, et al. "T Cell-Macrophage Interactions Influence Chemotherapeutic Response in Ovarian Cancer Patients." *International journal of molecular sciences.* July 10, 2026. PMID 42511520. (open access) **225.** Scrocciolani C, et al. "3D Bioprinting of High-Grade Serous Ovarian Cancer Cells: Workflow for Gelatin-Based Bioink Formulation with Hyaluronic Acid and Printability Assessment." *ACS applied bio materials.* June 26, 2026. PMID 42360787. (subscription access) **226.** Yang J, et al. "\[Advances in diagnosis and treatment of malignant ovarian germ cell tumors\]." *Zhonghua fu chan ke za zhi.* July 25, 2026. PMID 42477923. (subscription access) **227.** Cheng LH, et al. "\[Experimental study on the regulation of long non-coding RNA Linc-ROR on the stemness properties of ovarian cancer stem-like cells under hypoxia\]." *Zhonghua fu chan ke za zhi.* July 25, 2026. PMID 42477920. (subscription access) **228.** Tomita M, et al. "A Case of Ovarian Seromucinous Borderline Tumor With a Predominant Serous Component Suggesting Serous Borderline Tumor With Mucinous Differentiation." *International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.* April 3, 2026. PMID 41930595. (subscription access) **229.** Xu X, et al. "A Multi-Omics and Single-Cell Framework Identifies ITGA1 as a Candidate Predictive Biomarker of Neoadjuvant Chemotherapy Response in Epithelial Ovarian Cancer." *BioFactors (Oxford, England).* 2026. PMID 42457640. (subscription access) **230.** Xiang L, et al. "A systematic review and meta-analysis of medical image-based artificial intelligence models for predicting metastasis in ovarian cancer." *European journal of obstetrics, gynecology, and reproductive biology.* May 4, 2026. PMID 42107239. (subscription access) **231.** Liu Y, et al. "Cinobufagin regulates the microRNA-149-3p/AFF4 axis to affect the proliferation and apoptosis of cisplatin-resistant ovarian cancer cells." *Journal of chemotherapy (Florence, Italy).* May 27, 2025. PMID 40432319. (subscription access) **232.** Youssef O, et al. "Cross-Platform Comparative Spatial Transcriptomics in High-Grade Serous Carcinoma." *Laboratory investigation; a journal of technical methods and pathology.* May 15, 2026. PMID 42142589. (subscription access) **233.** Niu S, et al. "Endometrioid Versus Seromucinous Borderline Ovarian Tumors: Divergent Molecular Signatures and a Shared Role as Precursors to Endometrioid Carcinoma." *International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.* April 2, 2026. PMID 41926359. (subscription access) **234.** Zeng T, et al. "ENO1 lactylation drives bevacizumab resistance through metabolic reprogramming and angiogenesis in ovarian cancer." *Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.* May 7, 2026. PMID 42134086. (subscription access) **235.** Zyla RE, et al. "GLI1 -Rearranged Tumors of the Gynecologic Tract : A Detailed Clinicopathologic Study of 10 Cases." *The American journal of surgical pathology.* April 3, 2026. PMID 41928465. (subscription access) **236.** Brown EG, et al. "Lipids in ovarian cancer ascites impair T cell activation by disrupting TCR dynamics." *Nature metabolism.* July 22, 2026. PMID 42486922. (subscription access) **237.** Liu H, et al. "LncRNA TRHDE-AS1 functions as a tumor suppressor in ovarian cancer via the miR-17-5p/PIK3R1 ceRNA regulatory axis." *Journal of molecular histology.* July 16, 2026. PMID 42461466. (subscription access) **238.** Strauel C, et al. "Matrix metalloproteinase-9 regulates cell adhesion and membrane protrusive activity of ovarian cancer cells." *FEBS open bio.* February 24, 2026. PMID 41732872. (subscription access) **239.** Sheykhi-Sabzehpoush M, et al. "Mechanistic insights into HAGLROS-mediated therapy resistance in ovarian cancer." *Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.* February 3, 2026. PMID 41632343. (subscription access) **240.** Sundararajan V, et al. "Mes/Stem-A ovarian cancer subtypes predict sensitivity to ATR inhibition." *Oncogene.* June 11, 2026. PMID 42277179. (subscription access) **241.** D'Angelo E, et al. "Mullerian adenosarcoma of the uterus, ovary and peritoneum: Whole transcriptomic digital spatial profiling (DSP) in a cohort of 42 tumors." *Human pathology.* April 1, 2026. PMID 41932512. (subscription access) **242.** Zhao Z, et al. "Multi-omics identification of SPON1-related risk model for predicting prognosis and drug response in ovarian cancer." *Functional & integrative genomics.* July 22, 2026. PMID 42481779. (subscription access) **243.** Paul BM, et al. "Natural products targeting cytokine-regulated SASP inflammation networks in Ovarian cancer: Implications on immune escape and molecular resistance." *Inflammopharmacology.* July 21, 2026. PMID 42479110. (subscription access) **244.** Veljovich DS, et al. "Palbociclib in Patients With Ovarian Cancer WithAlterations: Results From the Targeted Agent and Profiling Utilization Registry Study." *JCO precision oncology.* July 15, 2026. PMID 42456088. (subscription access) **245.** Mályi A, et al. "Papillary Thyroid Carcinoma With an STRN::ALK Fusion Arising From a Mature Ovarian Teratoma." *International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.* August 11, 2025. PMID 40961468. (subscription access) **246.** Wang Y, et al. "Patient Engagement and Symptom Outcomes in a Provider-Guided Online Symptom Management Intervention: Mixed Methods Study." *Journal of medical Internet research.* July 23, 2026. PMID 42492066. (subscription access) **247.** Xie MM, et al. "Plasma trimethylamine N-oxide and related metabolites and overall survival of high-grade serous ovarian cancer: a nested case-control study." *European journal of nutrition.* July 8, 2026. PMID 42418014. (subscription access) **248.** Pires IS, et al. "Polymer Molecular Weight Influences Cancer Cell Surface Retention and Cytokine Presentation by Layer-by-Layer Nanoparticles." *ACS nano.* July 28, 2026. PMID 42442729. (subscription access) **249.** Kimura A, et al. "RNA-Seq Profiling Reveals Transcriptional Changes in Phosphorylation-Site Mutants of Brg1." *Genes to cells : devoted to molecular & cellular mechanisms.* July 2026. PMID 42469951. (subscription access) **250.** Li Y, et al. "SNRPD2-CPSF7-UBE2K axis drives ovarian cancer progression via alternative splicing-polyadenylation crosstalk." *Oncogene.* May 7, 2026. PMID 42098443. (subscription access) **251.** Künzle T, et al. "Spatial analysis of paraneoplastic cerebellar degeneration in ovarian cancer with anti-Yo syndrome and SCA1." *Journal of neurology.* July 27, 2026. PMID 42509533. (subscription access) **252.** Huang R, et al. "Spatial transcriptomics in ovarian biology technologies: computational challenges, and biological insights." *Reproduction (Cambridge, England).* July 3, 2026. PMID 42391613. (subscription access) **253.** Xie NW, et al. "Splenic Granulomatous Lesions Mimicking Metastases on 18 F-FDG PET/CT in a Patient With Ovarian Cancer." *Clinical nuclear medicine.* July 17, 2026. PMID 42537211. (subscription access) **254.** An J, et al. "STK38/L promote tissue growth and cancer by inhibiting the Hippo pathway." *Genes & development.* July 1, 2026. PMID 42128666. (subscription access) **255.** Bhardwaj S, et al. "The current molecular landscape of endometrial and ovarian carcinomas: insights and practical updates." *Seminars in diagnostic pathology.* July 1, 2026. PMID 42442082. (subscription access) **256.** Hashimoto E, et al. "The iron-sulfur cluster assembly factor FDX2 is required for tumor initiation but not for growth of established tumors in transplantation models." *The Journal of biological chemistry.* May 27, 2026. PMID 42208897. (subscription access) **257.** Eubler K, et al. "The RNA-binding protein Pumilio-2 has roles in the regulation of proliferation and innate immunity of human KGN granulosa tumor cells." *Reproduction (Cambridge, England).* July 3, 2026. PMID 42308542. (subscription access) **258.** Chen Y, et al. "The translation landscape of ovarian clear cell carcinoma indicates that RBM4 plays a pro-oncogenic role in tumor progression." *Oncogene.* June 5, 2026. PMID 42249082. (subscription access) --- *A note on how this digest was made: This edition was built by searching PubMed for papers published in July 2026, using targeted searches across the ovarian, fallopian tube, and peritoneal cancer landscape (PARP inhibitors, immunotherapy and ADCs, BRCA/HRD and hereditary risk, surgery, platinum resistance, early detection, subtypes, survivorship, disparities) plus a dedicated qualitative search. Papers summarized in full are open-access under a permitted license (CC0, CC BY, CC BY-SA, CC BY-ND, or CC BY-NC); on-topic papers under other licenses are listed by citation only. A companion methodology report, available separately, documents the full search-and-screening process and every paper reviewed.*

This Month in Ovarian Cancer Research

Published